Muscular Dystrophy Coordinating Committee (MDCC) Agenda Topics
2024
March
Exercise in Muscular Dystrophies: Current Understanding and Future Directions
November
Action Plan Renewal Working Groups Reports
2023
April
MDCC Member Organization Strategic Plans
Proposal to Renew Action Plan
December
Recent Advances Toward Regulatory Approvals for DMD
MDCC Member Organization Strategic Plans
2022
May
Drug Repurposing
October
Innovative Outcome Measures
2021
June
Respiratory and Sleep Complications of Muscular Dystrophies
December
Strategies to Increase Inclusion of Racial and Ethnic Minorities in Research Studies
2020
June
Gaps and Opportunities in Patient-Reported Outcome Measures
December
Newborn Screening for Rare Diseases: Current Landscape and Future Directions
2019
March
Best Practices for Patient Registries
November
Patient-Focused Drug Development
2018
April
Lessons Learned from Drug Approvals in Rare Neuromuscular Diseases
September
Strategies to Accelerate Accurate Genetic Diagnosis of Pediatric and Adult Muscular Dystrophies
2017
June
Partnerships in Supporting Training and Career Development
Therapeutic and Assistive Devices for the Muscular Dystrophies
December
MDCC Member Organization Support for MDCC Action Plan topics
2016
April
Sharing of Clinical Trial Data Through Public/Private Partnerships
Patient Access to Care, Services and Medical Equipment
November
Ethics of Pediatric Clinical Trials
Prospects for New Investigators in the Muscular Dystrophies
2015
March
Discussion of Draft 2015 Action Plan for the Muscular Dystrophies
Implementation of Care Guidelines
November
Muscular Dystrophy Biomarkers